news
Protein activation discovery could widen access to cancer immunotherapy
The activation of the protein p53 was shown to boost immune responses against cancer tumours in mice in a new study, potentially widening access to immunotherapy.
List view / Grid view
Proteomics
whitepaper
Infographic: Top reasons to select Bethyl bulk antibodies
10 reasons to choose Bethyl antibodies and reagents from Fortis Life Sciences for your applications.
whitepaper
ebook: Optimise your high value cell lines
As interest in biotherapeutic proteins grows, the need to reduce cell line development costs and the time to market is more critical than ever.
whitepaper
Guide: Eight tips for ensuring a successful ELISA
Learn quick technical tips to optimise your ELISA workflow, including how to: select the right ELISA kit, avoid contamination and normalise data.
news
Structural changes in SARS-CoV-2 Alpha and Beta variants revealed
A study has uncovered previously unknown properties of the Spike protein from the SARS-CoV-2 Alpha and Beta variants.
news
New technique developed for identifying therapeutic nanobodies
Researchers have used a new method for discovering nanobodies to identify potential therapeutics against SARS-CoV-2 infection.
news
Dual antibodies effective against SARS-CoV-2 variants in animal study
In mice and hamsters, therapies made from two antibodies were found to be mostly effective against a range of SARS-CoV-2 variants.
article
Covalent fragment screening in cell-based phenotypic models of disease: a collaborative approach
The application of chemical perturbation approaches in phenotypic models is often used to identify protein targets for therapeutic discovery. Increasingly, small molecule fragments which covalently bind to their protein targets are being used to explore the druggable proteome and the resulting fragment‑protein interactions are characterised by chemoproteomic techniques. In this…
article
Screening for COVID-19 drugs
With the COVID-19 pandemic ongoing, new therapeutic drugs to combat SARS-CoV-2 are still required. In this article, Professor Arvind Patel from the Medical Research Council (MRC) – Centre for Virus Research (CVR) at the University of Glasgow spoke with Drug Target Review’s Victoria Rees to discuss the work being done…
article
Better therapeutic antibodies by design
The binding specificity and high binding affinity of therapeutic antibodies makes them an ideal therapy for treating a wide range of human disorders. Advancements in antibody technologies have resulted in huge development success along with a boost in novel and improved treatment strategies. However, specific challenges and considerations are faced…
article
How to mix the best anti-SARS-CoV-2 cocktail
Neutralisation resistance generated by Spike (S) protein mutations in Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) poses a challenge to antibody therapies for COVID-19. Antibody cocktails targeting the S protein receptor binding domain (RBD) are one way to avoid viral neutralisation escape, however only certain antibody combinations are currently effective.…
news
New approach for treating cystic fibrosis shows success in mice
Researchers have developed a potential strategy to treat cystic fibrosis, using oligonucleotides to correct certain gene defects.
article
Drug Target Review Antibodies ebook 2021
Within this ebook, find articles on antibodies to combat SARS-CoV-2 and an evaluation of the various therapeutic forms they can take.
news
Two COVID-19 vaccines show safety and strong immunity in infant model
Two groups of infant rhesus macaques received one of two potential COVID-19 vaccines, which were shown to elicit high levels of neutralising antibodies.
article
The other end of the antibody: Fc biology and immunotherapy
Dr Björn Frendeus outlines how the growing biology surrounding the inhibitory Fc receptor FcγRIIb defines a target for improving existing and future antibody treatments.